唾液冲洗液HPV DNA与启动子高甲基化联合检测用于复发性HPV阳性口咽癌
联合面板AUC为0.88,优于单一标志物(AUC 0.69-0.78),阳性标志物早于临床检测2.4±1.6个月,并与约40倍复发风险相关(OR 36.4)。筛查分析中联合HPV DNA、甲基化EDNRB和PAX5将AUC提升至0.93。
要点
- 唾液HPV DNA联合甲基化EDNRB面板检测复发AUC达0.88,优于单一标志物。
- 阳性标志物早于临床复发检测2.4±1.6个月,与近40倍复发风险相关。
- 筛查中联合HPV DNA、甲基化EDNRB和PAX5的AUC提升至0.93。
核心结论
- 唾液冲洗液中高危HPV DNA或异常高甲基化检测与口咽鳞状细胞癌的存在及复发相关。
- 同时靶向HPV DNA和甲基化标志物可能有助于长期监测。
研究设计与样本
- 筛查分析另纳入21例未治疗患者和40例对照。
- 采用ROC曲线和多变量逻辑回归模型评估生物标志物组合性能。
主要发现
- 治疗后队列中8例(16.3%)出现局部区域复发。
- 复发与饮酒(OR 6.12;95%CI 0.26-3.79)和晚期淋巴结病变(OR 2.21;95%CI 1.52-3.01)相关。
- HPV DNA联合甲基化EDNRB面板检测复发AUC为0.88,单一标志物AUC为0.69-0.78。
- 阳性生物标志物早于临床检测2.4±1.6个月,与复发风险OR 36.4(95%CI 1.15-45.22)相关。
- 筛查分析中单一标志物AUC为0.59-0.83,联合HPV DNA、甲基化EDNRB和甲基化PAX5面板AUC提升至0.93。
临床怎么用
- 唾液冲洗液HPV DNA联合甲基化EDNRB检测可用于治疗后口咽癌患者的长期监测。
- 阳性结果可能早于临床复发 detection 数月,提示需密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The incidence and survivorship of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) are increasing. Presence of HPV DNA and epigenetic alterations in salivary rinses are independently associated with clinical prognosis. We evaluated the utility of a combined panel in detecting disease recurrence during surveillance. We also assessed the assay's applicability in screening for HPV+ OPSCC. STUDY DESIGN: Retrospective cohort study. SETTING: Two tertiary academic hospitals. SUBJECTS AND METHODS: Forty-nine patients with posttreatment OPSCC were enrolled. Separately, 21 treatment-naive patients and 40 controls were included in the screening analysis. Salivary rinses were obtained from these cohorts and biomarker levels were quantified. Receiver operative characteristic (ROC) curves and multivariate logistic models were used to assess performance of biomarker combinations. RESULTS: Eight patients (16.3%) in the posttreatment cohort developed locoregional recurrence. Recurrence was associated with alcohol use (odds ratio [OR], 6.12; 95% confidence interval [CI], 0.26-3.79) and advanced nodal disease (OR, 2.21; 95% CI, 1.52-3.01). A panel of HPV DNA and methylated EDNRB improved detection of recurrent disease (area under the curve [AUC], 0.88) compared to single markers (AUC, 0.69-0.78). Positive biomarkers preceded clinical detection by 2.4 ± 1.6 months and was associated with nearly 40-fold risk of recurrence (OR, 36.4; 95% CI, 1.15-45.22). Within the screening analysis, single biomarkers demonstrated moderate sensitivity and specificity (AUC, 0.59-0.83) in the detection of primary disease. A panel combining HPV DNA markers with methylated EDNRB and methylated PAX5 improved AUC to 0.93. CONCLUSION: Detection of high-risk HPV DNA or aberrant hypermethylation in oral rinses is associated with presence and recurrence of OPSCC. Targeting both markers in saliva may have utility in long-term surveillance.
引用
- Shen S, Saito Y, Ren S, et al. Targeting Viral DNA and Promoter Hypermethylation in Salivary Rinses for Recurrent HPV-Positive Oropharyngeal Cancer. Otolaryngol Head Neck Surg. 2020. PMID: 32041482. doi:10.1177/0194599820903031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。